# Study to Evaluate Efficacy and Safety of Sunitinib in Renal Cell Carcinoma Progressed to 1L Immunotherapy Treatment.

> **NCT03066427** · PHASE2 · COMPLETED · sponsor: **Spanish Oncology Genito-Urinary Group** · enrollment: 23 (actual)

## Conditions studied

- Clear Cell Renal Carcinoma

## Interventions

- **DRUG:** Sunitinib

## Key facts

- **NCT ID:** NCT03066427
- **Lead sponsor:** Spanish Oncology Genito-Urinary Group
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2017-05-10
- **Primary completion:** 2020-09-22
- **Final completion:** 2020-09-22
- **Target enrollment:** 23 (ACTUAL)
- **Last updated:** 2020-11-13

## Collaborators

- [object Object]
- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03066427

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03066427, "Study to Evaluate Efficacy and Safety of Sunitinib in Renal Cell Carcinoma Progressed to 1L Immunotherapy Treatment.". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT03066427. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*